MedTrace Logo

Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial)

NCT02268071 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 403

Last updated 2023-06-22

No results posted yet for this study

Summary

The STOP-Trial is a prospective multicenter nonrandomized open study on grade I hypertension, performed by General practitioners.

The study will be conducted in parallel in the Clinical Investigation Center Plurithematic (CIC-P)1433 of Nancy (the study coordinating center) by the general practitioners investigators of the CIC-P.

The main purpose of the study is to determine the factors associated with the rate of patients remaining normotensive one year after stopping their antihypertensive monotherapy or low dose dual therapy:

* white coat hypertension
* primary diagnosis by home blood pressure measurements (HBPM) /ambulatory blood pressure measurements (ABPM) /clinical measure
* initial blood pressure level
* compliance
* therapeutic class versus others
* age
* gender
* weight variation
* modification of lifestyle
* concomitant treatments and associated substances
* ...

The primary endpoint will be the rate of normotensive patients at one year (i.e. HBPM values \<135/85 mmHg).

Conditions

Interventions

DRUG

Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence

For patients with average of HBPM values \<135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Jean-Marc BOIVIN, MD, PhD · Centre d'Investigation Clinique Plurithématique/INSERM/CHU de Nancy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-10
Primary Completion
2020-10-21
Completion
2020-10-21

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02268071 on ClinicalTrials.gov